We are excited to announce that CRYOPDP will soon be part of the Cryoport family.

The agreement has been signed, and the acquisition is expected to close within 60 days subject to customary closing conditions.

CRYOPDP's strong presence in the US, Europe and Asia Pacific and Cryoport's US extensive footprint will provide enormous benefits to our clients as well as create synergies across the organizations making CRYOPDP even stronger, more flexible, agile and innovative.

We’re thrilled to announce, in accordance with the agreement initially announced on March 2, 2020, that CRYOPDP is now part of Hivest Capital Partners. The independent French Private Equity firm has acquired CRYOPDP’s capital and aims to consolidate the company as a major international player with an extended network and market reach. 

We are proud to announce, CRYOPDP has won an award for "Best Clinical Trial Logistics Provider” by the Asia-Pacific Bioprocessing Excellence Awards. 

This award is given annually to industry leaders and trend-setters in the biopharma scene who demonstrate the highest acknowledgment, superior quality, and service excellence. It is a prestigious honor that serves to recognize the best of the best within our field. 

Following the recent escalation of restrictions in response  to COVID-19 in several countries, we are making every effort to transport our customers shipments to agreed service levels. We are constantly monitoring the evolving situation worldwide and executing our strong contingency plans as necessary.

However, new regulations and limitations set by government authorities and airlines may affect the speed and/or the cost of delivery of shipments at certain times for some destinations.